- Policy
- 100 billion won more for new drug 500 billion won megafund
- by Lee, Hye-Kyung Jun 19, 2023 06:00am
- The government plans to create an additional fund of 100 billion won this year following the creation of a 500 billion won 'mega fund' last year to strengthen investment and export support for the pharmaceutical and bio industries. However, since a proper drug price valuation must necessarily accompany first-in-class development support, i
- Company
- ADHD drug Strattera discontinues supply in Korea
- by Kim, Jin-Gu Jun 19, 2023 06:00am
- The domestic supply of the ADHD (Attention-Deficit·Hyperactivity Disorder) treatment ‘Strattera (atomoxetine) was completely discontinued in Korea. Its supplier Lilly Korea said, “We have currently discontinued its supply, with no plans for resupply. According to the pharmaceutical industry on the 17th, Lilly Korea recently notified Bo
- Company
- Epkinly designated as an orphan drug in Korea
- by Eo, Yun-Ho Jun 19, 2023 06:00am
- Epkinly, the first bispecific antibody drug involving T cells, has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety recently announced that it designated AbbVie's lymphoma treatment Epkinly as an orphan drug. The specific indication is relapsed or refractory DLBCL with a history of two or more systemic therapie
- Company
- Forxiga generics occupy 20% of mkt 2 mths into their release
- by Kim, Jin-Gu Jun 19, 2023 05:59am
- ‘Forxiga (dapagliflozin)’ generics have increased their market share to 20% within 2 months of entry into the market. With fierce competition unfolding in the prescription field, the total market size expanded to exceed KRW 10 billion per month. However, since so many products were released at the same time, the average monthly prescr
- Policy
- Awareness of Korean pharmaceuticals, ranked 7th out of 13
- by Lee, Hye-Kyung Jun 16, 2023 05:55am
- In an awareness survey conducted on overseas consumers in countries leading the world's bio-health industry, they ranked 7th out of 13 countries in the pharmaceutical sector, 7th out of 15 countries in the medical device sector, 3rd out of 12 countries in the cosmetics sector, and 3rd out of 12 countries in the medical service sector. It was ran
- Policy
- RMP evaluation cycle Up to 3 yrs What items can be changed?
- by Lee, Hye-Kyung Jun 16, 2023 05:55am
- Items that can change the risk management plan (RMP) cycle up to three years have been determined. The Ministry of Food and Drug Safety recently enacted an amendment (draft) to the 'drug risk management plan guidelines and specifically included the targets for changing the RMP reporting cycle, related documents, and procedures for reviewing t
- Company
- Lipiodol is in stable supply despite price cuts
- by Nho, Byung Chul Jun 16, 2023 05:55am
- Guerbet Korea X-ray contrast agent Lipiodol Ultra (iodized oil), which caused controversy over supply and demand, faced a drug price cut due to the entry into a generic on the 1st of last month. Still, it is understood that the supply is stable so far. In the meantime, Guerbet Korea has been negotiating with the health authorities for reasons
- Product
- Series of non-face-to-face medical care platforms close down
- by Jung, Sae-Im Jun 16, 2023 05:55am
- More than 30 platforms that were created while temporary non-face-to-face medical care was allowed, initiated self-restructuring. With the government starting a non-face-to-face medical care pilot project under the ‘only allowed for returning patient’ rule rather than allowing the first-time visits requested by the platforms, companies
- Company
- Ultomiris under review as myasthenia gravis Tx in Korea
- by Eo, Yun-Ho Jun 16, 2023 05:54am
- The paroxysmal nocturnal hemoglobinuria (PNH) treatment ‘Ultomiris’ is seeking to secure an indication for myasthenia gravis (gMC) in Korea. According to industry sources, AstraZeneca Korea submitted an application to the Ministry of Food and Drug Safety and is being reviewed for the indication to treat adults with generalized myastheni
- Opinion
- [Reporter's view] Homework left by ASCO 2023’ hot topic
- by Jung, Sae-Im Jun 16, 2023 05:53am
- There is one thing in common with the major studies that drew attention at this year's Annual Conference of the American Society of Clinical Oncology (ASCO 2023). It has achieved successful results in adjuvant therapy targeting early cancer where surgery is possible. New drugs used in terminal cancers, such as metastasis and recursation, have
